NCT02759497

Brief Summary

One of the most common and serious complications in decompensated cirrhotic patients (DCPs) is bacterial infection.The most common infections in DCPs are cases of spontaneous bacterial peritonitis (SBP), which account for 40% 70% of cases, followed by urinary tract infections, pneumonia and cellulitis. Serum amyloid A (SAA) and C-reactive protein (CRP) are acute-phase proteins predominantly produced and secreted by hepatocytes. Other cells including lymphocytes, monocytes, and macrophages can also produce these proteins. The induction of SAA and CRP synthesis is triggered by a number of cytokines, chiefly IL-6, which is released from a variety of cell types, but mainly from macrophages and monocytes at inflammatory sites

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2016

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 1, 2016

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 3, 2016

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2020

Completed
Last Updated

June 20, 2017

Status Verified

June 1, 2017

Enrollment Period

4.6 years

First QC Date

May 1, 2016

Last Update Submit

June 17, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of patients with elevated serum amyloid A

    6months

Study Arms (2)

Serum amyloid A level in SBP

serum amyloid A level

Other: serum amyloid A level

Serum amyloid A level in cirrhosis

Serum amyloid A level

Other: serum amyloid A level

Interventions

serum amyloid A level (SAA)

Serum amyloid A level in SBPSerum amyloid A level in cirrhosis

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Decompensated cirrhosis with SBP Decompensated cirrhosis without SBP

You may qualify if:

  • Decompansated cirrhosis with ascites, defined by a combination of any of the following:
  • Laboratory findings
  • Endoscopic results
  • Ultrasound
  • Histology

You may not qualify if:

  • Creatinine\>1.5 mg/dl
  • Other infection e.grespiratory,UTI ,gastrointestinal and skin infection.
  • Hepatocellular carcinoma
  • Other extrahepatic malignancy e.g ; chest
  • Any significant psychiatric illness or other medical comorbidity.
  • Any degenerative diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sherief Abd-Elsalam

Cairo, Egypt

RECRUITING

Study Officials

  • Rehab Badawi, Consultant

    Hepatology and gastroenterology dept.-Tanta

    PRINCIPAL INVESTIGATOR
  • Sherief Abd-Elsalam, Consultant

    Division of Gastroenterology and Hepatology- Tanta

    STUDY CHAIR
  • Walaa Elkhalawany, Consultant

    Hepatology and gastroenterology dept.-Tanta

    STUDY CHAIR
  • Reham Elkhouly, Consultant

    Hepatology and gastroenterology dept.-Tanta

    STUDY CHAIR
  • Mona Watany, Consultant

    clinical pathology dept.-Tanta

    STUDY CHAIR
  • Samah Soliman, Consultant

    Hepatology and gastroenterology dept.-Tanta

    STUDY CHAIR
  • Mai Khalaf, resident

    hepatology dept.-Tanta

    STUDY CHAIR

Central Study Contacts

Sherief Abd-Elsalam, Consultant

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consultant liver and GIT diseases- Tanta university hospital

Study Record Dates

First Submitted

May 1, 2016

First Posted

May 3, 2016

Study Start

March 1, 2016

Primary Completion

October 1, 2020

Study Completion

November 1, 2020

Last Updated

June 20, 2017

Record last verified: 2017-06

Locations